A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
2상
완료
NCT06454630
| 대상 질환 | Venous Thromboembolism |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Regeneron Pharmaceuticals |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 179 명 |
|---|
| 중재(약물) | REGN7508, Enoxaparin |
|---|
| 시작일 | 2024년 6월 27일 |
|---|
| 완료일 | 2024년 11월 19일 |
|---|
| 결과 공개일 | 2026년 3월 2일 |
|---|
요약
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related diseases after unilateral total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)
Through day 12 · percentage of participants
| REGN7508 | 7.1 percentage of participants |
|---|
| Enoxaparin | 17.2 percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.